FRM
FPRX

Fox Run Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Fox Run Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-12,132
Closed -$113K – 772
2018
Q4 		$113K Sell
12,132
-8,803
-42% -$105K 0.06% 459
2018
Q3 		$291K Sell
20,935
-3,016
-13% -$44.9K 0.13% 356
2018
Q2 		$379K Buy
+23,951
New +$418K 0.12% 346
2018
Q1 		– Sell
-17,614
Closed -$386K – 1009
2017
Q4 		$386K Buy
+17,614
New +$566K 0.11% 375
2016
Q3 		– Sell
-10,800
Closed -$447K – 761
2016
Q2 		$447K Buy
+10,800
New +$470K 0.22% 154

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fox Run Management's FPRX Position: Q1 2019 in Review

Fox Run Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2019, closing a stake of 12,132 shares — an estimated $113K sold.

Fox Run Management first reported a position in FPRX in Q2 2016 and held it in 5 quarters. The position peaked at $447K in Q2 2016. 113 funds tracked by Wall St. Rank hold FPRX as of Q1 2019.

  • Fox Run Management reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • Fox Run Management sold 12,132 Five Prime Therapeutics, Inc. shares in Q1 2019, an estimated $113K.
  • Fox Run Management first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 5 quarters.
  • Fox Run Management's Five Prime Therapeutics, Inc. position peaked at $447K in Q2 2016.
  • 113 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2019.

Based on Fox Run Management's 13F filing for Q1 2019, filed 17 Oct 2019.